ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1947

Prolactin Promotes Survival of Immature B Cells from MRL/Lpr Mice

Karina Chavez-Rueda1, Rocio Flores-Fernández1, Francisco Blanco-Favela1, María Legorreta-Haquet2, Luis Chávez-Sánchez2, Rafael Hernández-González3 and Emiliano Tesoro-Cruz3, 1UIM en Inmunologia, IMSS, Mexico DF, Mexico, 2IMSS, Mexico DF, Mexico, 3Departamento de Investigación Experimental y Bioterio, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico DF, Mexico

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: B cells, SLE and prolactin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B cell Biology and Targets in Autoimmune Disease: Systemic Lupus Erythematosus and Related Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose

Prolactin (PRL) plays an important role in modulating the immune response. PRL is secreted by the pituitary gland as well as many other organs and cells, such as lymphocytes. In B cells, PRL enhances antibody production, including those with self-specificity; as such, PRL has been associated with B cell-triggered autoimmune diseases such as systemic lupus erythematosus (SLE). In this study, our aims were to determine the expression of PRL-receptor during bone marrow B cell development and whether the presence of high PRL serum concentration influences absolute numbers of developing populations and disease outcome in lupus-prone murine models. 

Methods

All of the mice experiments were performed in accordance with approved guidelines established by Mexico (Norma Oficial Mexicana NOM-062-ZOO-1999). The NIH Guide for the Care and Use of Laboratory AnimalsC57BL/6 mice were purchased from Harlan, the MRL/MpJ (MRL) and MRL/MpJFASlpr(MRL/lpr) mice were purchased from the Jackson Laboratory. The pro-B, pre-B and immature B cells from the bone marrow of mice were purified by flow cytometry and were assayed for the expression of PRL receptor mRNA and protein. The nine weeks old mice were treated with metoclopramide for six weeks to induce high levels of PRL, accelerate SLE symptoms, and the absolute cell numbers of bone marrow B cell subsets were analysed.

Results

Using real time-PCR and flow cytometry, we observed that the PRL-receptor is expressed in bone marrow early B cells (pro-B, pre-B, immature); in lupus prone mice the highest level of expression was found in pro-Bs and immature cells. Immature cells from lupus-prone strains showed a decrease in the absolute numbers of cells with high PRL-receptor expression in response to PRL. Since immature B cells are permanently being subjected to anti-self-elimination mechanisms, we assessed the survival in immature B cell line and immature B cells from mice. Immature B cells incubated with an anti-IgM antibody have increased survival rates in hyperprolactinemic conditions, in the same way in immature B cells lines the mRNA expression of Bcl-xL was increased. 

Conclusion

Taken together, these data indicate an important effect of PRL on B cell development, both favouring positive selection and counteracting mechanisms against self-specificity. In this scenario, increased PRL levels would result in the maturation of B cell clones with self-reactivity and an increased risk for developing auto-immune diseases


Disclosure:

K. Chavez-Rueda,
None;

R. Flores-Fernández,
None;

F. Blanco-Favela,
None;

M. Legorreta-Haquet,
None;

L. Chávez-Sánchez,
None;

R. Hernández-González,
None;

E. Tesoro-Cruz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prolactin-promotes-survival-of-immature-b-cells-from-mrllpr-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology